Paratek Pharmaceuticals, Inc. - FORM 8-K - EX-99.3 - CROSS-STUDY COMPARISON SLIDE - October 19, 2010

Attached files

file filename
8-K - FORM 8-K - Paratek Pharmaceuticals, Inc.d8k.htm
EX-99.2 - SCRIPT FOR CONFERENCE CALL - Paratek Pharmaceuticals, Inc.dex992.htm
EX-99.4 - RISK FACTORS CONTAINED IN PART II, ITEM 1A OF THE TRANSCEPT PHARMACEUTICALS, INC - Paratek Pharmaceuticals, Inc.dex994.htm
EX-99.1 - PRESS RELEASE ANNOUNCING INTERMEZZO HIGHWAY DRIVING STUDY PRELIMINARY ANALYSIS - Paratek Pharmaceuticals, Inc.dex991.htm

 

Exhibit 99.3

LOGO

 

Mean change in SDLP for various hypnotics and blood alcohol concentration (BAC) levels

BAC, zopiclone and US-marketed hypnotics

Brookhuis K. Hum. Psychopharmacol. Clin. Exp. 1998;13:S64–S69.

8 10-11h

10-11h post-dose

7 post-dose

10-11h

(cm) 6 post-dose

SDLP 5

Intermezzo®

in 4 Highway driving study 10-11h

post-dose

3 9h post-dose 10-11h

change post-dose BAC

2 3h 0.05%

Mean post-dose

4h

1 post-dose

0

Inter me In zzo® t e3 . 5 rmezmg zo ® 3.

5

Zopiclone mg 7 . 5 m g BAC

0 . 05% BAC

0. Zo 08 piclone % 7 . 5 m Flurazepam g Se1 c 5 obarbital mg Fl200 uramg z ep am 30 Flurmg azepam 30 m g

Note: The cross study comparisons reflected above should be viewed with caution. Cross study meta-analyses are subject to interpretational and other risks due to a number of factors, including unaccounted for variables that may render comparisons difficult or invalid, and potential inconsistencies in methods of normalizing study results. Additional studies from the Brookhuis publication reflecting data from drugs not approved in the United States are not reflected above. The above collection of studies is not presented as a complete presentation of highway driving studies analyzing hypnotic drugs approved in the United States.

Paratek Pharmaceuticals, Inc. Reports